These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7657870)

  • 21. Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: A multicentric retrospective analysis.
    Di Lernia V; Stingeni L; Boccaletti V; Calzavara Pinton PG; Guarneri C; Belloni Fortina A; Panzone M; Corazza M; Neri I; Cambiaghi S; Lasagni C; Ficarelli E; Gisondi P
    J Dermatolog Treat; 2016 Oct; 27(5):395-8. PubMed ID: 26571044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of two cyclosporine dosage regimens for the treatment of severe psoriasis.
    Yoon HS; Youn JI
    J Dermatolog Treat; 2007; 18(5):286-90. PubMed ID: 17852632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability.
    Zachariae H; Abrams B; Bleehen SS; Bräutigam M; Burrows D; Ettelt MJ; Fry L; Happle R; Haustein UF; Ganslandt J; Jung EG; Knop J; Kühne KH; Mellein B; Mørk NJ; Rogers S; Schmidt AG; Schopf RE; Sumner M; Taube KM; Weidinger G; Wurdel C; Zahn E
    Dermatology; 1998; 196(2):231-6. PubMed ID: 9568413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of erythrodermic psoriasis with low-dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO).
    Dermatology; 1993; 187 Suppl 1():30-7. PubMed ID: 8369577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Remission of ordinary psoriasis following a short clearance course of cyclosporin.
    Levell NJ; Shuster S; Munro CS; Friedmann PS
    Acta Derm Venereol; 1995 Jan; 75(1):65-9. PubMed ID: 7747540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclosporine A in the treatment of psoriasis: a clinical and mechanistic perspective.
    Griffiths CE; Voorhees JJ
    J Invest Dermatol; 1990 Nov; 95(5 Suppl):53S-55S. PubMed ID: 16788634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short-contact anthralin treatment augments therapeutic efficacy of cyclosporine in psoriasis: a clinical and pathologic study.
    Gottlieb SL; Heftler NS; Gilleaudeau P; Johnson R; Vallat VP; Wolfe J; Gottlieb AB; Krueger JG
    J Am Acad Dermatol; 1995 Oct; 33(4):637-45. PubMed ID: 7545705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study.
    Thaçi D; Bräutigam M; Kaufmann R; Weidinger G; Paul C; Christophers E
    Dermatology; 2002; 205(4):383-8. PubMed ID: 12444336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alterations in renal function in psoriasis patients treated with cyclosporine, 5 mg/kg/day.
    Margolis DJ; Guzzo C; Johnson J; Lazarus GS
    J Am Acad Dermatol; 1992 Feb; 26(2 Pt 1):195-7. PubMed ID: 1552052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Focus on five patients treated with cyclosporine up to 62 months.
    Bardazzi F; Magnano M; Balestri R; Patrizi A; Tengattini V
    J Dermatolog Treat; 2016 Oct; 27(5):427-9. PubMed ID: 26822802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Etanercept reduces symptoms and severity of psoriasis after cessation of cyclosporine therapy: results of the SCORE study.
    Micali G; Wilsmann-Theis D; Mallbris L; Gallo G; Marino V; Brault Y; Germain JM
    Acta Derm Venereol; 2015 Jan; 95(1):57-61. PubMed ID: 24682319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective analysis of combination methotrexate-cyclosporine therapy in moderate-severe psoriasis.
    Mohanan S; Ramassamy S; Chandrashekar L; Thappa DM
    J Dermatolog Treat; 2014 Feb; 25(1):50-3. PubMed ID: 23469768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study.
    Vena GA; Galluccio A; Pezza M; Vestita M; Cassano N
    J Dermatolog Treat; 2012 Aug; 23(4):255-60. PubMed ID: 21756153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A study of the use of drugs in patients suffering from psoriasis and their impact on quality of life.
    Karamata VV; Gandhi AM; Patel PP; Sutaria A; Desai MK
    Indian J Pharmacol; 2017; 49(1):84-88. PubMed ID: 28458428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with systemic cyclosporine A treatment in severe childhood psoriasis.
    Bulbul Baskan E; Yazici S; Tunali S; Saricaoglu H
    J Dermatolog Treat; 2016 Aug; 27(4):328-31. PubMed ID: 26651208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term low-dose cyclosporine therapy for psoriasis.
    Campbell JL; Zug KA
    J Am Acad Dermatol; 1997 Oct; 37(4):671-2. PubMed ID: 9344222
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy of cyclosporin A (CyA) in psoriasis: an overview of dose/response, indications, contraindications and side-effects.
    Zachariae H; Steen Olsen T
    Clin Nephrol; 1995 Mar; 43(3):154-8. PubMed ID: 7774070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
    Pariser DM; Green LJ; Stein Gold L; Sugarman JL; Lin T; Pillai R
    J Drugs Dermatol; 2018 Jul; 17(7):723-726. PubMed ID: 30005093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of preprandial versus postprandial administration of low-dose cyclosporin microemulsion (Neoral) in patients with psoriasis vulgaris.
    Hashizume H; Ito T; Yagi H; Takigawa M; Kageyama H; Furukawa F; Hata M; Shirahama S; Tanaka M; Higashishiba T; Machida H; Tsushima T; Matsushita K
    J Dermatol; 2007 Jul; 34(7):430-4. PubMed ID: 17584318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.
    Ohtsuki M; Morita A; Igarashi A; Imafuku S; Tada Y; Fujita H; Fujishige A; Yamaguchi M; Teshima R; Tani Y; Nakagawa H
    J Dermatol; 2017 Oct; 44(10):1105-1111. PubMed ID: 28543617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.